<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>
  • Using technology in tumor genomics to develop precision cancer therapeutics

    Investor Relations

Press Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

Dec 21, 2017
Activation of second trial site for Phase 1b/2 clinical trial of PCM-075, in combination with standard-of care, to evaluate dose and scheduling, and preliminary anti-leukemic activity
Dec 14, 2017
PCM-075, Trovagene's Polo-like Kinase 1 (PLK1) inhibitor enhances activity of abiraterone in mCRPC tumor cells and may represent a novel combination treatment option in mCRPC
 

email print rss
3:34
3:34
Wistia video thumbnail - Susann-Berz Patient Video- Home Page

Thanks for reporting a problem. We'll attach technical data about this session to help us figure out the issue. Which of these best describes the problem?

Any other details or context?

Cancel
message